Bausch & LombBLCO -0.29%77 9-Day RSI is 79.93 as of Jul. 06, 2026. GuruFocus rates BLCO with a GF Score™ of 77/100 and a GF Value™ of $18.63 (Fairly Valued). The stock has 9 warning signs investors should review. Among 869 Medical Devices & Instruments companies, Bausch & Lomb ranks worse than 98.62% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-06), Bausch & Lomb's 9-Day RSI is 79.93.
The industry rank for Bausch & Lomb's 9-Day RSI or its related term are showing as below:
BLCO's 9-Day RSI is ranked worse than 98.62% of 869
companies
in the Medical Devices & Instruments industry
Industry Median: 52.31
vs BLCO: 79.93
Bausch & Lomb (NYSE:BLCO) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Bausch & Lomb 9-Day RSI Related Terms
BLCO vs ISRG, BDX, MDLN: 9-Day RSI Comparison
For the Medical Instruments & Supplies subindustry, Bausch & Lomb's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch & Lomb 9-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Bausch & Lomb's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch & Lomb (BLCO) has a 9-Day RSI of 79.93 as of Jul. 06, 2026. According to the industry distribution chart, Bausch & Lomb ranks #857 out of 869 companies in the Medical Devices & Instruments industry, placing it in the top 98.6%.
Is Bausch & Lomb's 9-Day RSI too high?
Bausch & Lomb's current 9-Day RSI is 79.93. The Medical Devices & Instruments industry median 9-Day RSI is 52.31. Bausch & Lomb's value of 79.93 is 52.8% above this industry median. Based on the distribution chart, Bausch & Lomb ranks #857 out of 869 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bausch & Lomb has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bausch & Lomb's 9-Day RSI compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bausch & Lomb ranks #857 out of 869 companies for 9-Day RSI. This places Bausch & Lomb in the lower half of its industry. The industry median 9-Day RSI is 52.31. Bausch & Lomb's value of 79.93 is 52.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Medical Devices & Instruments company?
The median 9-Day RSI among Medical Devices & Instruments companies is 52.31, based on 869 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bausch & Lomb's current 9-Day RSI of 79.93 is 52.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median 9-Day RSI is 52.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bausch & Lomb's current 9-Day RSI is 79.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch & Lomb stock overvalued right now?
Based on GuruFocus' analysis, Bausch & Lomb (BLCO) is currently considered Fairly Valued. The stock's GF Value™ is $18.63, compared to a current price of $17.11 — trading 8.2% below its estimated fair value. The current 9-Day RSI is 79.93 and 52.8% above the Medical Devices & Instruments industry median of 52.31. Bausch & Lomb's overall GF Score™ is 77/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Bausch & Lomb (BLCO), the current 9-Day RSI is 79.93 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bausch & Lomb (BLCO) Overvalued in 2026?
Based on GuruFocus' analysis, Bausch & Lomb stock appears to be undervalued.
The current stock price of $17.11 is trading 8.2% below its estimated GF Value™ of $18.63.
GuruFocus considers Bausch & Lomb to be Fairly Valued.
Key valuation signals for BLCO:
9-Day RSI: 79.93
GF Value™: $18.63 vs. price of $17.11 (8.2% below fair value)
Industry Position: 52.8% above the Medical Devices & Instruments median (#857 of 869)
No single metric tells the full story. See the BLCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
77GF Score
Get the complete analysis for BLCO
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLCO has been successfully added to your 